Issues: The development of effective treatments for alcohol use disorders represents an important public health concern. Quetiapine, a multiple receptor antagonist at 5-HT(1A) and 5-HT(2A), dopamine D(1) and D(2), histamine H(1), and adrenergic α(1) and α(2) receptors, is an atypical antipsychotic medication that has recently shown promise for the treatment of alcoholism.
Approach: This manuscript reviews the rationale and empirical literature suggesting that quetiapine may be useful for the treatment of alcohol use disorders, including a discussion of its putative neurobiological and biobehavioural mechanisms of action.
Key Findings: The effects of quetiapine on drinking outcomes may be due to its effects on mood, anxiety and sleep, which may help alleviate protracted withdrawal symptoms and address psychiatric comorbidities often associated with alcohol use disorders.
Implications: These findings have implications to treatment development for alcoholism and suggest that the scientific study of quetiapine for alcoholism warrants further resources and attention.
Conclusion: Quetiapine has advanced as a potentially promising pharmacotherapy for alcoholism. Additional research is needed to more clearly ascertain its clinical utility as a stand-alone treatment for this indication, as well as to identify patients who are more likely to respond favourably to this medication.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1465-3362.2010.00185.x | DOI Listing |
Alzheimers Dement
December 2024
Department of Pharmacology, Central University of Punjab, Bathinda, Bathinda, Punjab, India.
Background: In previous studies, we found that quetiapine activates the AKT signaling which further inhibits the action of GSK3β. Quetiapine has been reported to possess neuroprotective potential in schizophrenia and other neurodegenerative models.
Method: On day 1 and 3, rats received bilateral intracerebroventricular (i.
Alzheimers Dement
December 2024
Mental Health Center, West China Hospital, Sichuan University, Chengdu, China.
Background: Behavioral and psychological symptoms of dementia (BPSD) are highly prevalent in people living with dementia. Atypical antipsychotics (AAPs) are commonly used to treat BPSD, but their comparative efficacy and acceptability are unknown.
Methods: This study was conducted following the guidelines of the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA).
Background: This scoping review focuses on the occurrence of tachyphylaxis, defined as reduced responsiveness upon reinitiating a previously effective medication. This phenomenon is previously documented in antidepressants and mood stabilizers.
Aim: To explore the frequency, treatment strategies, and predictability of tachyphylaxis across all psychotropic medications.
Drugs Aging
January 2025
Pharmacy Outcomes Research Group, Kaiser Permanente, 12254 Bellflower Blvd, Downey, CA, 90242, USA.
Background And Objective: Quetiapine is a Food and Drug Administration (FDA) approved second-generation antipsychotic. It is also commonly used at low dose for its sedative properties to treat insomnia in the older population. Quetiapine at standard doses has been associated with increased risk of cerebrovascular events, cognitive decline, and mortality in patients with dementia, especially within older adults.
View Article and Find Full Text PDFNeurol Int
December 2024
Department of Obstetrics, Gynecology and Reproductive Sciences, School of Medicine, University of Miami Miller, Miami, FL 33136, USA.
Neurosyphilis-induced dementia represents a severe manifestation of tertiary syphilis, characterized by cognitive and neuropsychiatric impairments. This condition arises from the progression of syphilis to the central nervous system, where the spirochete causes damage through invasion, chronic inflammation, and neurodegeneration. The pathophysiology involves chronic inflammatory responses, direct bacterial damage, and proteinopathies.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!